BridgeBio Pharma Inc. trailing returns
How BridgeBio Pharma Inc. (BBIO) has performed over the last day, week, month and year, over 5 years, and since inception, through November 17, 2026 — price return and dividends side by side, with the worst drop inside each window.
Trailing returns by period#
Data provided bySource: Twelve DataTo 2026-11-17. Price return + dividends = total return. Worst drop: the deepest fall in the price from a high inside the window, and when it bottomed.
| Period | Price | DivsDividends | Total | Worst drop |
|---|---|---|---|---|
| Cumulative · the change over the window | ||||
| 1 day | -0.7% | +0.0% | -0.7% | — |
| 5 days | -2.4% | +0.0% | -2.4% | -3.4%Nov 17 |
| 1 month | +15.7% | +0.0% | +15.7% | -4.6%Nov 5 |
| YTD | +0.4% | +0.0% | +0.4% | -29.8%Oct 13 |
| Per year (CAGR) · the cumulative total return beneath | ||||
| 1 year | +14.8% | +0.0% | +14.8% CAGR | -29.8%Oct 2026 |
| 5 years | +10.7% | +0.0% | +10.7% CAGR+66.6% total | -88.7%May 2022 |
| Since 2019Since inception (2019) | +14.9% | +0.0% | +14.9% CAGR+178.8% total | -92.8%May 2022 |
Growth of BBIO#
Actual level with dividends reinvested (solid); dashed lines are each window's constant-rate path from start to today.
- 5 years+10.7%/year · +66.6%
Methodology#
Trailing returns measure from the closest close about N years before the latest close (2026-11-17). Cumulative return is the total change over the window; annualized return is the compound annual growth rate (CAGR), shown for windows of a year or more. Price return is the change in BBIO's closing price; total return reinvests dividends (from its split- and dividend-adjusted closes); the dividends column is the difference between the two. The worst drop is the largest fall in the closing price from a high to a later low inside the window, the way a drawdown is usually quoted. See the year-by-year returns for the calendar breakdown. Past performance does not predict future returns; not investment advice.
FAQ#
- What is BridgeBio Pharma Inc.'s return since inception?
- Since 2019, BridgeBio Pharma Inc. (BBIO) has compounded at about +14.9% a year — +178.8% in total.
